ESR1 and ductal breast carcinoma in situ: Patients with ER-positive, PR-positive invasive breast cancer tend to respond better to hormonal therapy than patients with an ER-positive, PR-negative invasive breast cancer [60], but there is no proof of such benefit in DCIS.